COMPOSITION
Each ml contains:
Testosterone Propionate USP 150 mg Fast-Acting
Oil base …………………………………… q.s
Description:
TESTO 150™ is IM and indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) idiopathic gonadotropin, deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Testosterone Propionate 150mg/ml.
Recommended Use:
For optimal results, Testosterone Propionate 150mg/ml is typically administered at a dose of 100-300 mg every other day. Adjustments may be necessary based on individual goals, response, and experience. The short half-life of testosterone propionate requires frequent injections to maintain stable blood levels. It can be effectively combined with other anabolic steroids for enhanced results. Post-cycle therapy (PCT) is essential to restore natural testosterone production after the cycle.
Side Effects:
Common side effects include water retention, increased blood pressure, and potential liver strain. Androgenic effects such as acne and hair loss may also occur. Estrogenic effects like gynecomastia can be managed with the use of aromatase inhibitors. Regular health monitoring is advised to mitigate risks.
TESTO 150
Short Description:
TESTO 150™ is IM and indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) idiopathic gonadotropin, deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Testosterone Propionate 150mg/ml.
0%
Strength
0%
Muscle Gain
0%
Fat Loss
0%
Side Effects







Reviews
There are no reviews yet.